Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM89NIB)

Drug Name
UX143 Drug Info
Indication
Disease Entry ICD 11 Status REF
Osteogenesis imperfecta LD24.K0 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DM89NIB

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sclerostin (SOST) TTYRO4F SOST_HUMAN Not Available [2]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Osteogenesis imperfecta
ICD Disease Classification LD24.K0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Sclerostin (SOST) DTT SOST 1.11E-01 0.9 2.87
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT05768854) An Open-label, Randomized, Active-Controlled, Phase 3 Study of Setrusumab Compared With Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta Types I, III or IV. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Ultragenyx Pharmaceutical